Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon α-2a and ribavirin in previously untreated subjects with hepatitis C

被引：13
|
作者：
McHutchison, J. G.
Everson, G. T.
Gordo, S.
Jacobson, R.
Kauffman, R.
McNair, L.
Muir, A.
机构：
[1] Duke Univ, Clin Res Inst, Div Gastroenterol, Durham, NC USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Hepatol, Denver, CO 80202 USA
[3] Henry Ford Hlth Syst, Detroit, MI USA
[4] Cornell Univ, Weill Med Coll, Div Gastroenterol & Hepatol, New York, NY USA
[5] Veertex Pharmaceut, Cambridge, MA USA
来源：
JOURNAL OF HEPATOLOGY | 2007年 / 46卷
关键词：
D O I：
10.1016/S0168-8278(07)62384-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
786
引用
收藏
页码：S296 / S296
页数：1
相关论文
共 50 条
  • [1] Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
    Forestier, Nicole
    Reesink, Hendrik W.
    Weegink, Christine J.
    McNair, Lindsay
    Kieffer, Tara L.
    Chu, Hui-May
    Purdy, Susan
    Jansen, Peter L. M.
    Zeuzem, Stefan
    [J]. HEPATOLOGY, 2007, 46 (03) : 640 - 648
  • [2] PROVE2: Phase II study of VX950 (telaprevir) in combination with peginterferon alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis
    Hezode, Christophe
    Ferenci, Peter
    Dusheiko, Geoffrey M.
    Pol, Stanislas
    Goeser, Tobias
    Bronowicki, Jean-Pierre
    Gharakhanian, Shahin
    Devonish, Desiree
    Kauffman, Robert
    Alam, John
    Pawlotsky, Jean-Michel
    Zeuzem, Stefan
    [J]. HEPATOLOGY, 2007, 46 (04) : 268A - 269A
  • [3] Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Jacobson, Ira M.
    Everson, Gregory T.
    Gordon, Stuart C.
    Kauffman, Robert
    McNair, Lindsay
    Muir, Andrew
    McHutchison, John G.
    [J]. HEPATOLOGY, 2007, 46 (04) : 315A - 316A
  • [4] Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Mchutchison, J. G.
    Everson, G. T.
    Gordon, S. C.
    Jacobson, I.
    Kauffinan, R.
    McNair, L.
    Muir, A.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S4 - S4
  • [5] CHARACTERIZATION OF A NEW AMINO ACID SUBSTITUTION (V36C) ASSOCIATED WITH TELAPREVIR (VX-950) RESISTANCE IN A PATIENT TREATED WITH TELAPREVIR, PEGINTERFERON ALPHA-2A AND RIBAVIRIN
    Barbotte, Laetitia
    Ahmed-Belkacem, Abdelhakim
    Chevaliez, Stephane
    Soulier, Alexandre
    Hezode, Christophe
    Pawlotsky, Jean-Michel
    [J]. HEPATOLOGY, 2008, 48 (04) : 1154A - 1154A
  • [6] Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a
    Reesink, H. W.
    Forestier, N.
    Weegink, C. J.
    Zeuzem, S.
    McNair, L.
    Purdy, S.
    Chu, H. -M.
    Jansen, P. L. M.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S272 - S272
  • [7] Neopterin and alt as markers of inflammation in chronic hepatitis C patients during administration of the HCVNS3-4a protease inhibitor telaprevir (VX-950) in combination with peginterferon ALFA 2a
    Gelderblom, H. C.
    Zeuzem, S.
    Weegink, C. J.
    Forestier, N.
    McNair, L.
    Purdy, S.
    Jansen, P. L. M.
    Reesink, H. W.
    [J]. JOURNAL OF HEPATOLOGY, 2007, 46 : S224 - S225
  • [8] Prove2 study: Treatment of chronic hepatitis C with telaprevir (TVR)in combination with peginterferon-alfa-2a with or without ribavirin, interim analysis results
    Hezode, Christophe
    Ferenci, Peter
    Dusheiko, Geoffrey M.
    Tran, Albert
    Grange, Jean-Didier
    Mathurin, Philippe
    Schmidt, Wolfgang E.
    Diepolder, Helmut
    Marcellin, Patrick
    Wedemeyer, Heiner
    Forestier, Nicole
    Mangels, Wendy
    Gharakhanian, Shahin
    Kauffman, Robert S.
    Alam, John
    Pawlotsky, Jean-Michel
    Zeuzem, Stefan
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A755 - A755
  • [9] Tolerability and antiviral effects in a 28-day study of the hepatitis C protease inhibitor Telaprevir (VX-950), in combination with peg-interforon-alpha-2a and ribavirin
    Lawitz, E.
    Rodriguez-Torres, M.
    Muir, A.
    Keane, J.
    Kieffer, T.
    McNair, L.
    McHutchison, J.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S239 - S239
  • [10] Prove1: Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Everson, Gregory T.
    Jacobson, Ira M.
    Gordon, Stuart C.
    McHutchison, John G.
    Kaufman, Robert
    McNair, Lindsay
    Muir, Andrew
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A758 - A758
12345